Detalhe da pesquisa
1.
Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phase II study.
Cancer Med
; 12(8): 9144-9155, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36734294
2.
Efficacy and feasibility of Apatinib and S-1 as a novel oral induction therapy in locally advanced head and neck squamous cell carcinoma: an exploratory phase 2 open-label, single-arm trial.
Front Oncol
; 13: 1072538, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37251944
3.
Adjuvant PD-1 antibody in recurrent, previously irradiated oral cavity cancer treated with salvage surgery.
Clin Transl Radiat Oncol
; 40: 100623, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37096116
4.
Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (Illuminate Trial).
Int J Surg
; 109(8): 2220-2227, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37288582
5.
Can adjuvant radiotherapy be omitted for oral cavity cancer patients who received neoadjuvant therapy and surgery? A retrospective cohort study.
Int J Surg
; 109(4): 879-886, 2023 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36999830
6.
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma.
Front Immunol
; 13: 813732, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35371031
7.
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.
Nat Commun
; 13(1): 5378, 2022 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36104359
8.
Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study.
Ther Adv Med Oncol
; 13: 17588359211013626, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33995600
9.
The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication.
Front Immunol
; 12: 618367, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34552580
10.
A Phase 2 Trial of Chemoradiation Therapy Using Weekly Docetaxel for High-Risk Postoperative Oral Squamous Cell Carcinoma Patients.
Int J Radiat Oncol Biol Phys
; 107(3): 462-468, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32126267
11.
Long-term results of elective mucosal irradiation for head and neck cancer of unknown primary in Chinese population: The EMICUP study.
Cancer Med
; 9(5): 1712-1720, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31953927
12.
Effect of oral supplements on the nutritional status of nasopharyngeal carcinoma patients undergoing concurrent chemotherapy: A randomized controlled Phase II trial.
J Cancer Res Ther
; 16(7): 1678-1685, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33565516
13.
A feasibility and safety study of concurrent chemotherapy based on genetic testing in patients with high-risk salivary gland tumors: Preliminary results.
Medicine (Baltimore)
; 97(17): e0564, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703045
14.
Longitudinal Body Composition Changes and the Importance of Fat-Free Mass Index in Locally Advanced Nasopharyngeal Carcinoma Patients Undergoing Concurrent Chemoradiotherapy.
Integr Cancer Ther
; 17(4): 1125-1131, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345816
15.
Tailored multimodality therapy guided by a two-step decision making process for head-and-neck cancer of unknown primary.
Oncotarget
; 7(26): 40095-40105, 2016 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27223430
16.
Multi-modality management for loco-regionally advanced laryngeal and hypopharyngeal cancer: balancing the benefit of efficacy and functional preservation.
Med Oncol
; 31(9): 178, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25131963